C-VQKQProsetta
small molecules, assembly modulation, multi-protein complexes
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-VQKQ
C-VQKQC-VQKQsmall molecules, assembly modulation, multi-protein complexes
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Prosetta's Cancer Drug: Latest NCI Test Results 100%/100% | Dharma Prasad LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agr
70% reduction in proliferation in key models like MCF7 (breast) and A549 (lung) ♦️ Strong selectivity for tumor cells, sparing normal cells This pan-cancer activity opens the door to a new therapeutic class, Smarter. Broader. Built to outsmart resistance. Read the full paper: https://lnkd.in/giQ6pnhJ Vishwanath R. Lingappa | Dharma Prasad | Prosetta Bioconformatics Pvt Ltd | The National Institutes of Health |BioRxiv | #cancerresearch #oncology #drugdiscovery #biotech #innovation #futureofmedicine #proteinbiology #assemblymodulators "> 70% reduction in proliferation in key models like MCF7 (br … s shown remarkable progress, particularly in moving from theory toward clinical application. A recent review in Frontiers in Oncology highlights how EV biomarkers are shifting the paradigm in colorectal cancer, and by extension, oncology overall. 𝐖𝐡𝐚𝐭’𝐬 𝐧𝐞𝐰: EVs now offer 𝐧𝐨𝐧-𝐢𝐧𝐯𝐚𝐬𝐢𝐯𝐞 𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜 opportunities in 𝘤𝘰𝘭𝘰𝘳𝘦𝘤𝘵𝘢𝘭 𝘤𝘢𝘯𝘤𝘦𝘳 screening, where traditional methods remain invasive and burdensome. 𝐓𝐡𝐞 𝐫𝐞𝐯𝐢𝐞𝐰 𝐡𝐢𝐠𝐡𝐥𝐢𝐠
Prosetta Biosciences - 2026 Company Profile, Funding, Competitors & Financials - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Inv … 19, 2012 6373372 Series B 4866711 5817101 3575592 4163884 Jun 07, 2012 2706369 Grant (prize money) 9656490 5502437 7951000 HHS Access funding benchmarks and valuations. Sign up today! View details of Prosetta Biosciences 's funding rounds and investors Prosetta Biosciences' founders and board of directors Founder? Claim Profile Prosetta Biosciences' employee count trend Prosetta Biosciences has 24 employees as of Mar 26. Here is Prosetta Biosciences 's em
Prosetta Bioconformatics Pvt Ltd Skip to content Prosetta Bioconformatics Pvt Ltd Facebook Twitter Instagram Youtube Menu Home About Career Contact Home About Career Contact Home About Career Contact Slide Background NEXT GENERATION DRUG DISCOVERY COMPANY Developing Drugs That Target Multi-Protein Complexes Slide Background NEXT GENERATION DRUG DISCOVERY COMPANY Developing Drugs That Target Multi-Protein Complexes slider_1 NEXT GENERATION DRUG DISCOVERY COMPANY Developing Drugs That Target Multi-Protein Complexes slider_1 NEXT GENERATION DRUG DISCOVERY COMPANY Developing Drugs That Target Mult … rce, Committees, Jury boards and Academic councils. He received his most recent award, Distinguished Alumni Award, from University of Mysore in the year 2020. Dr. Prasad received his PhD from Centre for DNA Fingerprinting and Diagnostics, University of Hyderabad in 2004. Vishwanath R. Lingappa, MD, PhD Director Vishwanath R. Lingappa is the Founder, Chief Technology Officer, and CEO of Prosetta Biosciences, Inc, in San Francisco. Since founding the company in 2003, he and his … is now an Emeritus Professor of Physiology at UCSF. He is recipient of a Kaiser Award for excellence in teaching and is a Fellow of the American Association for the Advancement of Science. Dr. Lingappa received his Ph.D. degree from The Rockefeller University in 1979, and the M.D. degree from Cornell University Medical College in 1980. Karl Manheim, BS, JD, LLM Director Karl Manheim is a Professor of Law at Loyola Law School (Los Angeles) where he teaches Constitutional Law,
Takeda to Study Prosetta Biosciences' CNS Compounds genprowebdirectory End Meta Pixel Code --> Facebook Linkedin RSS Twitter Youtube GEN Edge Featured News Multimedia Content News Insights Topics Artificial Intelligence Bioprocessing Cancer Drug Discovery Genome Editing Infectious Diseases OMICs Translational Medicine Magazine Browse Issues Subscribe Multimedia Summits Webinars GEN Live Learning Labs Podcasts Videos Resources A-Lists eBooks/Perspectives Tutorials Peer-Reviewed Journals GEN Biotechnology Re:Gen Open New Products Subscribe Get GEN Magazine Get GEN eNewsletters Search Facebo
Prosetta Biosciences, Inc. Announces Closing Of Private Placement Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Multimedia Gall … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Prosetta’s Oncology Program Wins ARPA-H Dash to Accelerate Health Outcomes Contest — Prosetta 0 Skip to Content About News Publications Contact Open Menu Close Menu About News Publications Contact Open Menu Close Menu About News Publications Contact Prosetta’s Oncology Program Wins ARPA-H Dash to Accelerate Health Outcomes Contest May 19 Written By Vishwanath Lingappa After 6 rounds of voting, Prosetta’s submission to the ARPA-H Dash to Accelerate Health Outcomes, “One Drug for All Cancers” based on our Oncology Program emerges as the champion! Dr. Renee Wegrzyn, Head of ARPA-H, makes th
News — Prosetta 0 Skip to Content About News Publications Contact Open Menu Close Menu About News Publications Contact Open Menu Close Menu About News Publications Contact News Vishwanath Lingappa 12/20/25 Vishwanath Lingappa 12/20/25 Oxidized MIF is an Alzheimer’s disease drug target relaying external risk factors to tau pathology Published in Cell Reports Medicine To read the full article please click here Read More Vishwanath Lingappa 12/18/25 Vishwanath Lingappa 12/18/25 Preclinical Evaluation of the Assembly Modulator PAV-615 in a Mouse Model of C9orf72-Associated ALS/FTD publi
Oncology Program — Prosetta 0 Skip to Content About News Publications Contact Open Menu Close Menu About News Publications Contact Open Menu Close Menu About News Publications Contact Oncology Programs View fullsize Cancer comprises the second highest cause of death for people in the United States, with over 600,000 fatalities annually. More than 100 different types of cancers, with a myriad of causes and clinical presentations have been characterized that contribute to this figure. Cancer can affect a variety of organs and tissues, from the brain to the blood. It may be attributable to
Prosetta featured on #TalkPolymath podcast — Prosetta 0 Skip to Content About News Publications Contact Open Menu Close Menu About News Publications Contact Open Menu Close Menu About News Publications Contact Prosetta featured on #TalkPolymath podcast May 10 Written By Vishwanath Lingappa As part of the ARPA-H Dash to Accelerate Heath Outcomes, Anuradha Lingappa, esq. from Prosetta makes an appearance on the #TalkPolymath Podcast to explain about our oncology program and how it feels to make it into the semifinals. Click here to watch the video about the other contestants and their tech
Prosetta Biosciences Inc: A New Approach to Cancer Treatment | Prosetta Biosciences Inc posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or … interview with President & CEO Byron Elton and Principal Scientist Dr. Adam Grant, we break down the novel science that gives CancerVax its competitive edge. Current treatments (like CAR T-cells) are limited to identifying surface proteins ("Marker 1"). CancerVax is on another level. We utilize mRNA technology delivered via lipid nanoparticles, but with a crucial distinction: our Smart mRNA payload is designed to further distinguish between healthy and cancer cells based
%PDF-1.4 %���� 1 0 obj > endobj 2 0 obj >stream application/pdf doi:10.1038/s42003-024-06130-8 A viral assembly inhibitor blocks SARS-CoV-2 replication in airway epithelial cells Li Du Fred Deiter Mohamed S. Bouzidi Jean-Noël Billaud Graham Simmons Prerna Dabral Suganya Selvarajah Anuradha F. Lingappa Maya Michon Shao Feng Yu Kumar Paulvannan Balaji Manicassamy Vishwanath R. Lingappa Homer Boushey John R. Greenland Satish K. Pillai Springer US Communications Biology, doi:10.1038/s42003-024-06130-8 Springer 2024-04-22T14:04:00+02:00 2024-04-22T12:32:07+05:30 2024-04-22T14:04:00+02:00 True iText … ����?+�|�c�ɨK�]s�y�Ճ�vN�E����Yg����zg���:qTO������J� � S �� 7�1Tѿ,uˍ���q��D�rfpޟ�˺��ҔڟF*��w� �!Oڧ݊�O��/�]s��>^ן�-o�& s\##���}��qW��c��[�`n��b��C��{L��;�6��{��v*�Uث�Wb��]��v*�Uث�Wb��R�0���˶Rjz��ok����:�{�*�;���O,G/���_�~J�*�o"�dh�w�k�nm =H�q�+Ӓ� �T{⬟v*�0�24�!�E}�,��zK�(cˉm�F��W���t���W~��ޔ� ^� J�)/+�����lƟ���+�9�-J����M1Wb��]��v*�U"����ڟ��\ɶ�P^D����ԭ�����IQ�� AA�- Rx�r�~�Uim늪� �8P=F��з#ኢ��P����4�b��h�*���U)d�ت� �T=쟺8��5���2�� ��RTt8��� … tvWdB8r+XfL9t9W0TT
bbToSAGW3jWMtTu7AVY+7HFCZ4q7FXYq7FXYq7FXYq7FXYq7FX//2Q== application/postscript xmp.did:ff27c8c7-b7fe-3245-888d-f648d03d9983 xmp.iid:ff27c8c7-b7fe-3245-888d-f648d03d9983 uuid:97d04392-abaf-4ad6-a84a-b9e929edabac uuid:f4181c51-9e92-43a9-a8b3-4416495a0dc5 uuid:97d04392-abaf-4ad6-a84a-b9e929edabac uuid:97d04392-abaf-4ad6-a84a-b9e929edabac saved xmp.iid:ff27c8c7-b7fe-3245-888d-f648d03d9983 2022-02-16T10:05:16+05:30 Adobe Illustrator 26.0 (Windows) / Adobe P … tvWdB8r+XfL9t9W0TT
bbToSAGW3jWMtTu7AVY+7HFCZ4q7FXYq7FXYq7FXYq7FXYq7FX//2Q== application/postscript xmp.did:ff27c8c7-b7fe-3245-888d-f648d03d9983 xmp.iid:ff27c8c7-b7fe-3245-888d-f648d03d9983 uuid:97d04392-abaf-4ad6-a84a-b9e929edabac uuid:f4181c51-9e92-43a9-a8b3-4416495a0dc5 uuid:97d04392-abaf-4ad6-a84a-b9e929edabac uuid:97d04392-abaf-4ad6-a84a-b9e929edabac saved xmp.iid:ff27c8c7-b7fe-3245-888d-f648d03d9983 2022-02-16T10:05:16+05:30 Adobe Illustrator 26.0 (Windows) / Adobe P … �� �a ��c#��4�qd��O�犗Lg�ɔ�nTebg����� ��Ң�� q�s.M� > endobj 699 0 obj >stream application/postscript Print 2023-01-12T17:16:38+05:30 2023-01-12T17:16:38+05:30 2023-01-12T17:16:36+05:30 Adobe Illustrator 26.0 (Windows) 256 196 JPEG /9j/4AAQSkZJRgABAgEBLAEsAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABABLAAAAAEA
AQEsAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf
Prosetta Biosciences Announces Novel Solution to COVID-19 Crisis - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Bay Prosetta Biosciences Announces Novel Solution to COVID-19 Crisis January 19, 2021 | 1 min read Twitter LinkedIn Facebook Email Print Prosetta Biosciences, a San Francisco biotechnology company, has developed novel small-molecule drugs that research indicates are effective not only against the COVID-19 virus, … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
San Francisco Biotech Prosetta Biosciences Grabs $31 Million - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Rele … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Bay San Francisco Biotech Prosetta Biosciences Grabs $31 Million December 3, 2015 | 2 min read Twitter LinkedIn Facebook Email Print Prosetta Biosciences, Inc. Announces Closing Of Private Placement SAN FRANCISCO , Dec. 3, 2015 /PRNewswire/ -- Prosetta Biosciences, Inc. (the "Company," or "Prosetta"), today anno … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Prosetta Biosciences And Takeda Pharmaceutical Co. Ltd., Enter Into Agreement To Discover And Develop Novel Compounds For Neurodegenerative Diseases - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Prosetta Biosciences And Takeda Pharmaceutical Co. Ltd., Enter Into Agreement To Discover And Develop Novel Compounds For Neurodegenerative Diseases May 2, 2016 | 2 min read Twitter LinkedIn Facebook Email Print SAN FRANCISCO , May 2, 2016 /PRNewswire/ -- Prosetta Biosciences, Inc. (the "Comp … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Zanbato: Prosetta Bio Go to zanbato.com Secure Login Select the platform you want to log in to ZX Inter-broker platform for trading private shares and trade execution capabilities ZXData Provide institutional, non-tender secondary trading data on private companies Go to zanbato.com Contact Prosetta Bio Legal Name Prosetta Biosciences, Inc. Headquarters San Francisco Sector BioTech Website http://www.prosetta.com/ Prosetta Biosciences is a San Francisco based biotech focused on novel antiviral research. Learn more about Prosetta Bio IPO. Secondary Pricing Information $ . ZX Index Value | Get Ac … will get back to you soon. Name * Email * Partner Type * Broker Wealth Manager Fund Manager Family Office High Net Worth Individual Employee Shareholder Other Organization Comments * I would like to learn more about trading Prosetta Bio stock How did you hear about us * Referred by a friend Internet search Other Who referred you to us? Describe how you heard about us. Your information entered here will only be used so we may respond to your inquiry. For more details, visit o
Prosetta 0 Skip to Content About News Publications Contact Open Menu Close Menu About News Publications Contact Open Menu Close Menu About News Publications Contact A new approach to drug discovery Prosetta Biosciences is a San Francisco based biotechnology company that creates innovative therapeutics for diseases. Our work focuses on identifying and advancing novel small molecules that modulate assembly of multi-protein complexes within cells. Our technology will transform the field of medicine because, in contrast to most drugs available today, assembly-modulators work in tandem with the bod
About — Prosetta 0 Skip to Content About News Publications Contact Open Menu Close Menu About News Publications Contact Open Menu Close Menu About News Publications Contact About Our Platform The Prosetta Platform has been applied to infectious and degenerative diseases alike. In contrast to most drugs available today, assembly-modulators work in tandem with the body’s own regulatory mechanisms and provide a new strategy for restoring homeostasis on the molecular level. To learn more about this revolutionary approach, visit the Prosetta Paradigm and Drug Discovery Platform pages. Our Pro